Auto&Car

Jul 31 2019

Biotech Stocks To Watch And Pharma Industry News, Stock News – Stock Market Analysis, pharma industry.#Pharma #industry


Technology

Visit the IBD Store to get started.

Technology

Biotech Stocks To Watch And Pharma Industry News

  • IBD STAFF
  • 3:27 PM ET

Pharma industryPharma industryPharma industryPharma industryPharma industry

One minute Dow Jones industrial average component Merck (MRK) might be doing battle with fellow drugmaker Bristol-Myers Squibb (BMY) over drugs that can ward off cancer.

The next, biotech giants like Amgen (AMGN) and Sanofi (SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences (GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis.

It’s a brave – and contentious – new world for pharmaceutical and biotechnology companies. It’s a realm where science is trying to develop landmark medicines that cure cancer, hepatitis and other life-threatening illnesses.

All the while it does a delicate dance with Wall Street and regulators – balancing public health issues with the demands of shareholders. Investors will find it tricky to navigate the sector, as companies can rise and fall at the drop of a hat.

Bookmark this page to stay on top of the latest news in the biopharma sector.

Biotech And Pharma News

Pharma industry

Pharma industry

Pharma industry

Pharma industry

Pharma industry

Pharma industry

Pharma industry

  • IBD STAFF | [email protected]

Pharma industryPharma industryPharma industryPharma industryPharma industry

Related news

Pharma industry

Gilead Sciences caught an upgrade Thursday following its Kite Pharma buyout. (Kris Tripplaar/Sipa USA/Newscom)

Does Gilead’s Kite Acquisition Offer A New Buying Opportunity?

5:16 PM ET Gilead caught an upgrade following its Kite buyout and the promise shown with new cancer drugs.

5:16 PM ET Gilead caught an upgrade following its Kite buyout and the.

Why Amgen Could Have An Edge Over These Rivals In Preventing Migraines
Why Medicines Co. Is Tumbling Despite $270 Million Deal
Dow’s Merck Announces $10 Billion Buyback, Increases Dividend
Teva’s Restructuring Plan: Another Case Of Been Here, Done That?
Which Stocks Are Showing Rising Relative Strength?
Is Biogen’s Multiple Sclerosis Franchise Getting A New Lease On Life?
Why Roche Cancer Trial Is Kick In The Teeth For Dow Stock Merck
Stocks Close Modestly Higher As Verizon Helps Prop Up The Dow

Today’s Spotlight

Improve Your Profits Now

Find the Next Big Winner

Finding the Right Stocks

More News

  • Pharma industry Bitcoin Retreats As Goldman CEO, Fed’s Quarles Raise Doubts
  • Pharma industry No. 1-Ranked Medical Stock Builds New Base As Peer Breaks Out
  • All-New Pricing from TradeStation. Open an Account Today. Promoted Content By TradeStation

Special Report

Pharma industry

AI News: Artificial Intelligence Trends And Leading Stocks

Track the latest artificial intelligence trends and the AI leaders driving them.

Pharma industry

Free Trial

Get instant access to exclusive stock lists, expert market analysis and educational tools with a free trial to IBD Digital.

Pharma industry

IBD Videos

Get market updates, educational videos, webinars, and stock analysis.

Pharma industry

Get Started

Learn how you can make more money with IBD s investing tools, top-performing stock lists, and educational content.

  • Connect With Us On
  • Pharma industry
  • Pharma industry
  • Pharma industry
  • Pharma industry
  • Pharma industry
  • Pharma industry

Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.

*Real-time prices by Bats®. Volume delayed. Real-time quote and/or trade prices are not sourced from all markets.

© 2000-2017 Investor’s Business Daily, Inc. All rights reserved

Written by CREDIT


Leave a Reply

Your email address will not be published. Required fields are marked *